Summary
Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease caused by a deficiency of the liver-specific peroxisomal enzyme alanine: glyoxylate aminotransferase (AGT). The disease is notable for its extensive heterogeneity at the clinical, biochemical, enzymic and molecular genetic levels. A study of 116 PH1 patients over the past 8 years has revealed four main enzymic phenotypes: (1) absence of both AGT catalytic activity and immunoreactive AGT protein (≈40% of patients); (2) absence of AGT catalytic activity but presence of immunoreactive protein (≈16% of patients); (3) presence of both AGT catalytic activity and immunoreactive protein (≈41% of patients), in most of which cases the AGT is mistargeted to the mitochondria instead of the peroxisomes; and (4) a variation of the mistargeting phenotype in which AGT is equally distributed between peroxisomes and mitochondria, but in which that in the peroxisomes is aggregated into matrical core-like structures (≈3% of patients). Various point mutations, all occurring at conserved positions in the coding regions of the AGT gene, have been identified in these patients. The five mutations discussed in the present study, which have been found in individuals manifesting all of the four major enzymic phenotypes, account for the expressed alleles in about half of all Caucasian PH1 patients. The most common mutation found so far leads to a Gly170 → Arg amino acid substitution. This mutation, in combination with a normally occurring Pro11 → Leu polymorphism, appears to be responsible for the unprecedented peroxisome-to-mitochondrion mistargeting phenotype.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allsop J, Jennings PR, Danpure CJ (1987) A new micro-assay for human liver alanine: glyoxylate aminotransferase.Clin Chim Acta 170: 187–193.
Cooper PJ, Danpure CJ, Wise PJ, Guttridge KM (1988) Immunocytochemical localization of human hepatic alanine: glyoxylate aminotransferase in control subjects and patients with primary hyperoxaluria type 1.J Histochem Cytochem 36: 1285–1294.
Danpure CJ (1989) Recent advances in the understanding, diagnosis and treatment of primary hyperoxaluria type 1.J Inher Metab Dis 12: 210–224.
Danpure CJ (1991) Molecular and clinical heterogeneity in primary hyperoxaluria type 1.Am J Kidney Dis 17: 366–369.
Danpure CJ, Jennings PR (1986) Peroxisomal alanine: glyoxylate aminotransferase deficiency in primary hyperoxaluria type I.FEBS Lett 201: 20–24.
Danpure CJ, Jennings PR (1988) Further studies on the activity and subcellular distribution of alanine: glyoxylate aminotransferase in the livers of patients with primary hyperoxaluria type 1.Clin Sci 75: 315–322.
Danpure CJ, Cooper PJ, Wise PJ, Jennings PR (1989) An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria.J Cell Biol 108: 1345–1352.
Danpure CJ, Purdue PE, Fryer P et al (1993) Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine: glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation.Am J Hum Genet 53: 417–432.
Gibbs DA, Watts RW (1970) The action of pyridoxine in primary hyperoxaluria.Clin Sci 38: 277–286.
Leumann EP (1985) Primary hyperoxaluria: an important cause of renal failure in infancy.Int J Pediatr Nephrol 6: 13–16.
Ludwig GD (1963) Renal calculi associated with hyperoxaluria.Ann NY Acad Sci 104: 621–637.
Minatogawa Y, Tone S, Allsop J et al (1992) A serine-to-phenylalanine substitution leads to a loss of alanine: glyoxylate aminotransferase catalytic activity and immunoreactivity in a patient with primary hyperoxaluria type 1.Hum Mol Genet 1: 643–644.
Nishiyama K, Funai T, Katafuchi R, Hattori F, Onoyama K, Ichiyama A (1991) Primary hyperoxaluria type 1 due to a point mutation of T to C in the coding region of the serine: pyruvate aminotransferase gene.Biochem Biophys Res Commun 176: 1093–1099.
Noguchi T, Takada Y (1979) Peroxisomal localization of alanine: glyoxylate aminotransferase in human liver.Arch Biochem Biophys 196: 645–647.
Oda T, Miyajima H, Suzuki Y, Ichiyama A (1987) Nucleotide sequence of the cDNA encoding the precursor for mitochondrial serine: pyruvate aminotransferase of rat liver.Eur J Biochem 168: 537–542.
Purdue PE, Takada Y, Danpure CJ (1990) Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1.J Cell Biol 111: 2341–2351.
Purdue PE, Allsop J, Isaya G, Rosenberg LE, Danpure CJ (1991a) Mistargeting of peroxisomall-alanine: glyoxylate aminotransferase to mitochondria in primary hyperoxaluria patients depends upon activation of a cryptic mitochondrial targeting sequence by a point mutation.Proc Natl Acad Sci USA 88: 10900–10904.
Purdue PE, Lumb MJ, Allsop J, Danpure CJ (1991b) An intronic duplication in the alanine: glyoxylate aminotransferase gene facilitates identification of mutations in compound heterozygote patients with primary hyperoxaluria type 1.Hum Genet 87: 394–396.
Purdue PE, Lumb MJ, Fox M et al (1991c) Characterization and chromosome mapping of a genomic clone encoding human alanine: glyoxylate aminotransferase.Genomics 10: 34–42.
Purdue PE, Lumb MJ, Allsop J, Minatogawa Y, Danpure CJ (1992a) A glycine-to-glutamate substitution abolishes alanine: glyoxylate aminotransferase catalytic activity in a subset of patients with primary hyperoxaluria type 1.Genomics 13: 215–218.
Purdue PE, Lumb MJ, Danpure CJ (1992b) Molecular evolution of alanine: glyoxylate aminotransferase 1 intracellular targeting. Analysis of the marmoset and rabbit genes.Eur J Biochem 207: 757–766.
Takada Y, Kaneko N, Esumi H, Purdue PE, Danpure CJ (1990) Human peroxisomall-alanine: glyoxylate aminotransferase. Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon.Biochem J 268: 517–520.
von Heijne G (1986) Mitochondrial targeting sequences may form amphiphilic helices.EMBO J 5: 1335–1342.
Watts RW, Veall N, Purkiss P (1983) Sequential studies of oxalate dynamics in primary hyperoxaluria.Clin Sci 65: 627–633.
Watts RW, Calne RY, Rolles K et al (1987) Successful treatment of primary hyperoxaluria type 1 by combined hepatic and renal transplantation.Lancet 2: 474–475.
Watts RWE, Danpure CJ, de Pauw L, Toussaint C (1991) Combined liver-kidney and isolated liver transplantations for primary hyperoxaluria type 1. The European experience.Nephrol Dial Transpl 6: 502–511.
Williams HE, Smith LH (1983) Primary hyperoxaluria. In Stanbury JB, Wyngaarden JB, Fredrickson DS et al, eds.The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 204–228.
Wise PJ, Danpure CJ, Jennings PR (1987) Immunological heterogeneity of hepatic alanine: glyoxylate aminotransferase in primary hyperoxaluria type 1.FEBS Lett 222: 17–20.
Yokota S, Oda T, Ichiyama A (1987) Immunocytochemical localization of serine: pyruvate aminotransferase in peroxisomes of the human liver parenchymal cells.Histochemistry 87: 601–606.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Danpure, C.J., Jennings, P.R., Fryer, P. et al. Primary hyperoxaluria type 1: Genotypic and phenotypic heterogeneity. J Inherit Metab Dis 17, 487–499 (1994). https://doi.org/10.1007/BF00711363
Issue Date:
DOI: https://doi.org/10.1007/BF00711363